A Study of Bortezomib With Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia.

Trial Profile

A Study of Bortezomib With Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jul 2012

At a glance

  • Drugs Bortezomib (Primary) ; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Methotrexate; Pegaspargase; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 May 2012 Actual patient number 31 added as reported by ClinicalTrials.gov.
    • 14 Dec 2011 Status changed from recruiting to completed.
    • 13 Dec 2011 Results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top